¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"amylase complex with immunoglobulin"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • complex position sense
    º¹ÇÕÀ§Ä¡°¨°¢
  • complex potential
    º¹ÇÕÀüÀ§
  • complex receptive field
    º¹ÇÕ¼ö¿ë¾ß
  • complex regional pain syndrome
    º¹ÇÕºÎÀ§ÅëÁõÁõÈıº
  • complex repetitive discharge
    º¹Çչݺ¹¹æÀü
  • complex simple fracture
    º¹Àâ´Ü¼ø°ñÀý
  • complex visual discrimination
    º¹Çսð¢ºÐº°
  • coordination complex
    ¹èÀ§°áÇÕº¹ÇÕü
  • castration complex
    °Å¼¼ÄÞÇ÷º½º
  • drug-induced immune complex
    ¾à¹°À¯¹ß¸é¿ªº¹ÇÕü
  • dentoalveolar complex
    Ä¡¾ÆÀÌÆ²º¹ÇÕ±¸Á¶
  • exstrophy-epispadias complex
    ¹æ±¤¿Ü¹ø¿äµµ»ó¿­º¹ÇÕ
  • ethmomaxillary complex
    ¹úÁýÀ§ÅλÀº¹ÇÕü, »ç°ñ»ó¾Çº¹ÇÕü
  • father complex
    ¾Æ¹öÁöÄÞÇ÷º½º
  • factor IX complex
    Á¦9ÀÎÀÚº¹ÇÕü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • complex visual discrimination
    º¹Çսð¢ºÐº°
  • coordination complex
    ¹èÀ§°áÇÕº¹ÇÕü
  • dentoalveolar complex
    Ä¡¾ÆÀÌÆ²º¹ÇÕ±¸Á¶
  • drug-induced immune complex
    ¾àÁ¦À¯¹ß¸é¿ªº¹ÇÕü
  • ego-alien complex
    ÀÚ¾ÆÀÌÁúÄÄÇ÷º½º
  • ethmomaxillary complex
    ¹úÁýÀ§ÅλÀº¹ÇÕü, »ç°ñ»ó¾Çº¹ÇÕü
  • exstrophy-epispadias complex
    ¹æ±¤¹øÁü¿äµµÀ§¿­¸²º¹ÇÕü
  • father complex
    ¾Æ¹öÁöÄÞÇ÷º½º
  • Golgi¡¯s complex
    °ñÁöº¹ÇÕü
  • human leukocyte antigen complex
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕü
  • immune complex
    ¸é¿ªº¹ÇÕü
  • inferiority complex
    ¿­µîÄÞÇ÷º½º, ¿­µî°¨
  • junctional complex
    ¿¬Á¢º¹ÇÕü
  • major histocompatibility complex
    ÁÖÁ¶Á÷ÀûÇÕº¹ÇÕü
  • Merkel cell-neurite complex
    Ã˰¢¼¼Æ÷½Å°æµ¹±âº¹ÇÕü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • ghon complex
    °ï º¹ÇÕü, Ghon º¹ÇÕü
  • golgi complex
    °ñÁöº¹ÇÕü
  • hypersensitivity reactions,type iii(imune complex-mediated)
    IIIÇü
  • immune complex
    ¸é¿ªº¹ÇÕü.
  • immune complex
    ¸é¿ªº¹ÇÕü
  • immune complex disease
    ¸é¿ªº¹ÇÕüº´.
  • immune complex measurement
    ¸é¿ªº¹ÇÕÃ¼ÃøÁ¤
  • immune complex mediated hypersensitivity
    ¸é¿ªº¹ÇÕü¸Å°³ °ú¹Î¹ÝÀÀ
  • immune complex urticaria
    ¸é¿ªº¹Çյε巯±â
  • immune complex vasculitis
    ¸é¿ªº¹ÇÕüÇ÷°ü¿°
  • immune complex vasculitis
    ¸é¿ªº¹ÇÕü¼º Ç÷°ü¿°(Øóæ¹ÜÜùêô÷àõ úìηæú)
  • immune complex-mediated
    ¸é¿ªº¹ÇÕü¸Å°³°ú¹ÎÁõ(Øóæ¹ÜÜùêô÷ØÚ˿ΦÚÂñø)
  • inner complex salt
    ³»Âø¿°(Ò®ó¹ç¤).
  • pore complex
    ÇÙ±¸¸Ûº¹ÇÕü
  • primary complex
    Ãʱ⺯ȭ±º(ôøÑ¢Ü¨ûùÏØ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • immunoglobulin G CSF/serum ratio
    ¸é¿ª±Û·ÎºÒ¸° G ³úô¼ö¾×/Ç÷û ºñ(À²)
  • immunoglobulin G index
    ¸é¿ª±Û·ÎºÒ¸° G Áö¼ö
  • immunoglobulin M
    ¸é¿ª±Û·ÎºÒ¸° M
  • immunoglobulin M formation
    ¸é¿ª±Û·ÎºÒ¸° M Çü¼º
  • immunoglobulin a nephropathy
    ¸é¿ª±Û·ÎºÒ¸°A½Åº´Áõ(Øó湡­ãìÜ»ñø)
  • immunoglobulin a(iga)
    ¸é¿ª±Û·ÎºÒ¸° A(Øó湡­)
  • immunoglobulin class
    ¸é¿ª±Û·ÎºÒ¸°Å¬·¡½º.
  • immunoglobulin cleavage
    ¸é¿ª±Û·ÎºÒ¸°ºÐÇÒ
  • immunoglobulin detection
    ¸é¿ª±Û·ÎºÒ¸°°ËÃâ
  • immunoglobulin domain
    ¸é¿ª±Û·ÎºÒ¸°¿µ¿ª.
  • immunoglobulin e(ige)
    ¸é¿ª±Û·ÎºÒ¸° E(Øó湡­)
  • immunoglobulin g(igg)
    ¸é¿ª±Û·ÎºÒ¸° G(Øó湡­)
  • immunoglobulin gene
    ¸é¿ª±Û·ÎºÒ¸°À¯ÀüÀÎÀÚ
  • immunoglobulin m(igm)
    ¸é¿ª±Û·ÎºÒ¸° M(Øó湡­)
  • immunoglobulin production
    ¸é¿ª±Û·ÎºÒ¸°»ý¼º<--»ý»ê>
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • complex glycoproteins
    º¹ÇÕ ´ç´Ü¹éÁú(ÜÜùêÓØÓ±ÛÜòõ)
  • complex hapten
    º¹ÇÕ(ÜÜùê) ÇÕÅÙ
  • complex ion
    º¹ÇÕ(ÜÜùê) ÀÌ¿Â
  • complex lipid
    º¹ÇÕÁöÁú(ÜÜùêò·òõ)
  • complex locus
    º¹ÇÕºÎÀ§(ÜÜùêÝ»êÈ)
  • complex medium
    º¹ÇÕ ¹è¾ç¾×(ÜÜùêÛÆå×äû)
  • complex oligosaccharides
    º¹ÇÕ(ÜÜùê) ¿Ã¸®°í»çÄ«¶óÀ̵å
  • complex RNA
    º¹ÇÕ(ÜÜùê) RNA
  • complex virion
    º¹ÇÕ(ÜÜùê) ºñ¸®¿Â
  • covalent enzyme-substrate complex
    È¿¼Ò±âÁú °øÀ¯°áÇÕü(ý£áÈÐñòõÍìêóÌ¿ùêô÷) (ÔÒ) enzymesubstrate compound
  • cytochrome c oxidase complex
    »çÀÌÅäÅ©·Ò c ¿Á½Ãµ¥À̽º º¹ÇÕü(ÜÜùêô÷) (ÔÒ) complex IV
  • dead-end complex
    Á¾¸»º¹ÇÕü(ðûØÇÜÜùêô÷)
  • enzyme-bridge complex
    È¿¼Ò°¡±³ º¹ÇÕü (ý£áÈÊ­ÎéÜÜùêô÷)
  • enzyme complex
    È¿¼Òº¹ÇÕü (ý£áÈÜÜùêô÷)
  • enzyme-inhibitor complex
    È¿¼Ò-ÀúÇØÁ¦ º¹ÇÕü (ý£áÈîÁúªð¥ÜÜùêô÷)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ACCR amylase-creatinine clearance ratio
AMS ablepharon-microstomia syndrome; acute mountain sickness; adenosylmethionine synthetase; aggravated ...
AMY, amy amylase
Cam amylase clearance
S-AMY serum amylase
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
anti-IgE Anti-immunoglobulin E
HIgG Human immunoglobulin G
IVIG IV immunoglobulin G
IgE Immunoglobulin E
IgG Immunoglobulin G
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • condyle-disc complex
    °úµÎ-¿øÆÇ º¹ÇÕü
  • coordination complex
    ¹èÀ§Âø¿°, ¹èÀ§ º¹ÇÕ¹°, ¹èÀ§ °áÇÕ º¹ÇÕü
  • disk-condyle complex
    ¿øÆÇ °úµÎ º¹ÇÕü
  • drug-induced immune complex
    ¾àÁ¦ À¯¹ß¼º ¸é¿ª º¹ÇÕü
  • ego-alien complex
    ÀÚ¾Æ ÀÌÁú ÄÄÇ÷º½º
  • electra complex
    ¿¤·ºÆ®¶ó ÄÞÇ÷º½º
    ÇÁ·ÎÀ̵åÀÇ ¼º°Ý ±¸Á¶·ÐÀÇ ¹ß´Þ ´Ü°è Áß ³²±Ù±âÀÎ 3¼¼¿¡¼­ 6¼¼ »çÀÌÀÇ ¿©ÀÚ ¾ÆÀ̰¡ ¾î¸Ó´Ï¸¦ ¾Æ¹öÁöÀÇ ¼ºÀû °ü½ÉÀÇ °æÀïÀÚ·Î º¸°Ô µÇ°í ¾î¸Ó´Ï¸¦ µÎ·Á¿öÇÏ°Ô µÇ¾î ¾î¸Ó´Ï¸¦ ¹è°ÝÇÏ°í ¾Æ¹öÁö¸¦ »ç¸ðÇÏ´Â Çö»óÀ¸·Î ¾î¸Ó´Ï¿ÍÀÇ µ¿ÀϽð¡ ¿©¾ÆÀÇ ºÒ¾ÈÀ» ÇØ°áÇØ ÁÖ´Â °ÍÀ¸·Î º¸ÀδÙ.
  • immune complex
    ¸é¿ª º¹ÇÕü
    Ç׿ø°ú Ç×üÀÇ Æ¯Á¤ °áÇÕ¹°. ¹ÙÀÌ·¯½º³ª ¼¼±Õ µî À̹°ÀÇ Ä¨ÀÔ¿¡ ´ëÇØ¼­ »ýü°¡ »ý»êÇÑ Ç×ü´Â À̹°ÀÎ Ç׿ø°ú °áÇÕÇÏ¿© ¸é¿ª º¹ÇÕü¸¦ ¸¸µç´Ù. À̴ Ž½Ä ¼¼Æ÷³ª º¸Ã¼¸¦ Ȱ¼ºÈ­ÇÏ¿© À̹°ÀÌ ¹«ÇØÇÑ °ÍÀ¸·Î ºÐÇØÇÏ´Â °ÍÀ» µµ¿Í »ýü ¹æ¾î¿¡ µµ¿òÀ» ÁØ´Ù. Á¶Á÷ Àå¾ÖÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ¸é¿ª º¹ÇÕ¼º ÁúȯÀ» ÀÏÀ¸Å°±âµµ ÇÑ´Ù.
  • immune complex-mediated
    ¸é¿ª º¹ÇÕü ¸Å°³¼º
  • intralaminar complex
    Ãþ³» º¹ÇÕü
  • major histocompatibility complex
    ÁÖ Á¶Á÷ ÀûÇÕü, ÁÖ Á¶Á÷ ÀûÇÕ º¹ÇÕü
    ÀÎü Á¶Á÷ÇüÀ» °áÁ¤ÇÏ´Â À¯ÀüÀÚ°¡ 6¹ø ¿°»öüÀÇ ÀÛÀº ºÐÀý¿¡ º¹ÇÕü¸¦ Çü¼ºÇϰí À־ ÀÌ À¯ÀüÀÚ ¿µ¿ªÀ» À̸£´Â ¿ë¾î.
  • mother, complex
    ¸ð º¹ÇÕü
  • complex neutrocclusion
    º¹ÇÕ Áß¼º ±³ÇÕ
    ¾È¸ð¿Í º¹ÀâÇÑ ±³Á¤ Ä¡·á¸¦ µ¿¹ÝÇÏ´Â Áß¼º ±³ÇÕ.
  • nasomaxillary complex
    ºñ »ó¾Ç º¹ÇÕü
  • nitrogenase complex
    Áú¼Ò °íÁ¤ È¿¼Ò º¹ÇÕü
  • Oedipus complex
    ¿ÀÀ̵ðǪ½º ÄÞÇ÷º½º
    ÇÐ·É Àü±â ¾Æµ¿ÀÌ ¹Ý´ë¼ºÀÇ ºÎ¸ð¸¦ È¥ÀÚ¼­ ¼ÒÀ¯ÇÏ°í ½ÍÀº ¿å¸ÁÀ» °¡Áö¸ç, °°Àº ¼ºÀÇ ºÎ¸ð¿¡°Ô °æÀï Àǽİú ÁúÅõ ÀǽÄÀ» °®°Ô µÇ´Â ½É¸®Àû Çö»ó.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
immunoglobulin domains Structural units of immunoglobulin heavy or light chains that are composed of approximately 110 amino acids. Light chains of an immunoglobulin are composed of one constant domain and one variable domain. Heavy chains are composed of either three or four constant domains and one variable domain.
(05 Mar 2000)
immunoglobulin E <immunology> Class of immunoglobulin (188 kD) associated with immediate type hypersensitivity reactions and helminth infections.
Present in very low amounts in serum and mostly bound to mast cells and basophils that have an immunoglobulin E specific Fc receptor (FceR). Immunoglobulin E has a high carbohydrate content and is also present in external secretions.
Heavy chain of epsilon type.
(30 Mar 1998)
immunoglobulin electrophoresis <immunology, investigation> A test that detects and measures the various immunoglobulins in the blood.
In the normal assay no monoclonal antibodies are detected but in multiple myeloma and chronic lymphocytic leukaemia a single clone of lymphocytes can produce one type of immunoglobulin that is detected in the electrophoresis as monoclonal (made by one cell clone).
(30 Mar 1998)
immunoglobulin G <immunology> The classical immunoglobulin class also called 7S IgG (150 kD).
Composed of two identical light and two identical heavy chains, the constant region sequence of the heavy chains being of the type. The molecule can be described in another way as being composed of two Fab and an Fc fragment.
The Fabs include the antigen combining sites, the Fc region consists of the remaining constant sequence domains of the heavy chains and contains cell binding and complement binding sites.
Immunoglobulin Gs act on pathogens by agglutinating them, by opsonising them, by activating complement mediated reactions against cellular pathogens and by neutralising toxins. They can pass across the placenta to the foetus as maternal antibodies, unlike other Ig classes. In humans four main subclasses are known, IgG2 differs from the rest in not being transferred across the placenta and IgG4 does not fix complement. Immunoglobulin G is present at 8-16 mg/ml in serum.
Synonym: gamma globulin.
(30 Mar 1998)
immunoglobulin gm allotypes Hereditary allotypic markers associated with the heavy chain of IgG.
(12 Dec 1998)
immunoglobulin G subclass deficiency A rare inherited disorder in which there are reduced levels of one or more IgG subclasses resulting from defective heavy chain genes or an abnormality in the regulation of immunoglobulin isotype switching.
(05 Mar 2000)
immunoglobulin idiotypes Unique, genetically controlled determinants present on antibodies whose specificity is limited to a single group of proteins (e.g., another antibody molecule or an individual myeloma protein). The idiotype appears to represent the antigenicity of the antigen-binding site of the antibody and to be genetically codetermined with it. The idiotypic determinants have been precisely located to the variable regions of both immunoglobin polypeptide chains.
(12 Dec 1998)
immunoglobulin inv allotypes Hereditary allotypic markers associated with the light chain of IgG.
(12 Dec 1998)
immunoglobulin isotypes The classes of immunoglobulins found in any species of animal. In man there are nine classes that migrate in five different groups in electrophoresis; they each consist of two light and two heavy protein chains, and each group has distinguishing structural and functional properties.
(12 Dec 1998)
immunoglobulin joining region Segment of light and heavy chains of mouse and human immunoglobulins where the genes for the variable region upstream join those of the constant region downstream (an important part of the antibody diversity mechanism). In the joining region of the light chain are the genes coding for amino acids 96 to 107.
(12 Dec 1998)
immunoglobulin M <immunology> An immunoglobulin M molecule (970 kD) is built up from five immunoglobulin G type monomers joined together, with the assistance of J chains, to form a cyclic pentamer.
Immunoglobulin M binds complement and a single molecule bound to a cell surface can lyse that cell. Immunoglobulin M is usually produced first in an immune response before immunoglobulin G.
The human red cell isoantibodies are immunoglobulin M antibodies. Heavy chain (mu chain) is rather larger than the heavy chains of other immunoglobulins.
(30 Mar 1998)
immunoglobulin superfamily <immunology> A large group of proteins with immunoglobulin like domains. most are involved with cell surface recognition events.
Sequence homologyy suggests that immunoglobulins, MHC molecules, some cell adhesion molecules and cytokines receptors share close homology and thus belong to a multigene family.
(30 Mar 1998)
immunoglobulin switch region Site on a segment of a B-cell immunoglobulin heavy-chain gene where recombination or rearrangement can occur, expressed as isotype or allotype switching, maturation of immune response, or recombination of DNA molecules. It is found on genes encoding all five immunoglobulin heavy chains.
(12 Dec 1998)
immunoglobulin variable region That region of the immunoglobulin (antibody) molecule that varies in its amino acid sequence and composition, confers the antigenic specificity, and is thought to comprise the binding site for the antigen. It is located at the n-terminus of the fab fragment of the immunoglobulin. It includes hypervariable and framework regions, vh family subgroups, and the complementarity-determining region.
(12 Dec 1998)
intravenous immunoglobulin <pharmacology> A sterile solution of concentrated antibodies extracted from healthy people. IVIG is used to prevent bacterial infections in people with low or inappropriate antibody production. Injected into a vein or muscle.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á